Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study
Background: There have been scarce data on the distribution of clozapine concentrations in comparison with the recommended range (350–600 ng/ml) or their relationship with side effects among patients with treatment-resistant schizophrenia. Furthermore, no studies have assessed the association betwee...
Main Authors: | Nobuyuki Nomura, Kohei Kitagawa, Ryuhei So, Fuminari Misawa, Masafumi Kodama, Hiroyoshi Takeuchi, Robert Bies, Thomas Straubinger, Christopher Banker, Yuya Mizuno, Masaru Mimura, Hiroyuki Uchida |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-05-01
|
Series: | Therapeutic Advances in Psychopharmacology |
Online Access: | https://doi.org/10.1177/20451253211016189 |
Similar Items
-
Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J).
by: Kohei Kitagawa, et al.
Published: (2020-01-01) -
Population Pharmacokinetics of Clozapine: A Systematic Review
by: Orwa Albitar, et al.
Published: (2020-01-01) -
Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia
by: Ismael Olmos, et al.
Published: (2019-01-01) -
Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients
by: David B. Menkes, et al.
Published: (2018-01-01) -
Pharmacoepidemiological and pharmacokinetic aspects of the use of clozapine and olanzapine - optimising therapy
by: Taylor, David Michael
Published: (2003)